Topic Highlight
Copyright ©2014 Baishideng Publishing Group Inc.
World J Gastroenterol. Dec 7, 2014; 20(45): 16935-16947
Published online Dec 7, 2014. doi: 10.3748/wjg.v20.i45.16935
Table 1 Clinical trials of lexipafant in acute pancreatitis
Ref.Study designSeverity of APNo.IntervalDosage and administrationMajor variablesOutcomes
Kingsnorth et al[74], 1995Multi-centerMix83< 48 h60 mg/d, i.v., × 3 dOrgan failurePositive
double-blindOFS
RCTIL6, IL8
McKay et al[75], 1997Multi-centerAPACHEII > 5,50< 72 h100 mg/d, i.v., × 7 dOFSPositive
double-blindGlasgowscore ≥ 3, andSystemic complications
RCTC-reactive protein ≥ 120 mg/LMortality
Johnson et al[76], 2001Multi-center double-blind RCTAPACHEII > 6290< 72 h100 mg/d, i.v., × 7 dSystemic sepsis Pseudocysts New organ failure. MortalityPositive in systemic sepsis and pseudocysts